Bayer's Footnoted Efficacy Claim In Baycol U.K. Journal Ad Found Misleading
Executive Summary
Bayer's Lipobay (cerivastatin) ad in a U.K. journal is misleading because it prominently displays only female efficacy data without properly tempering it, the panel of the Prescription Medicines Code of Practice Authority ruled.